The Staphylococcus aureus Network Adaptive Platform Trial protocol: New tools for an old foe

alexandrossfakianakis shared this article with you from Inoreader The Staphylococcus aureus Network Adaptive Platform Trial protocol: New tools for an old foe via Clinical Infectious Diseases Advance Access Abstract Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15-30%. Despite this, fewer than 3000 people have been randomised into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for SAB infections being difficult to complete at scale using traditional clinical trial methods. Here we provide the rationale and framework for an adaptive platform trial applied to SAB infections. We detail the design features of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial that will enable multiple questions to be answered as efficiently as possible. The SNAP trial will commence enrolling patients across multiple countries in 2022 with an estimated target sample size of 7000 participants. This approach may serve as an exemplar to increase efficienc y of clinical trials for other infectious diseases syndromes. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.